Company: IOBT
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047744
Chunk: 252

Company: IO Biotech, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 252
---
 expansion of our business and do not anticipate paying cash dividends in the foreseeable future.

Stockholders

As of March 24, 2025, we had 65,880,914 shares of common stock outstanding held by 10 holders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.

Equity Compensation Plans

The following table details information regarding our existing equity compensation as of December 31, 2024:

    Plan Category
     
    Securities to be Issued Upon Exercise of Outstanding Options and Warrants (in thousands)(a)

    Weighted Average Exercise Price of Outstanding Options and Warrants(b)

    Number of Securities Remaining Available for Issuance Under Equity Compensation Plans (Excluding Securities reflected in Column (a))(in thousands) (c)

    Equity compensation plans approved by security holders

    8,370

    $
    5.43

    423

    Equity compensation plans not approved by security holders

    598

    $
    1.71

    1,666

       Total

    8,968

    $
    5.18

    2,089

See “Item 8. Financial Statements and Supplementary Data - Notes to the Consolidated Financial Statements - Note 12, “Equity-Based Compensation” for additional information on compensation plans under which equity securities of the registrant are authorized for issuance. 

Use of Proceeds

Recent Sales of Unregistered Securities

None.

Use of Proceeds From Registered Securities

On November 9, 2021, we completed our IPO in which we issued and sold 8,222,500 shares of common stock, $0.001 par value per share, including 1,072,500 shares of common stock sold pursuant to the underwriters’ exercise of their option to purchase additional shares of common stock. The offer and sale of the shares in the IPO was registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-260301), which was filed with the SEC on October 15, 2021 and subsequently amended and declared effective on November 4, 2021, and the prospectus included therein (the “Prospectus”). The underwriters of the IPO were Morgan Stanley